Effect of the P450 oxidoreductase*28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 807-812

  Zhang, Jing Jing ^a   Zhang, Hua ^a   Ding, Xiao Liang ^a   Ma, Sheng ^a   Miao, Li Yan ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

CYP3A5,3; Pharmacokinetics; POR,28; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; CYTOCHROME P450 REDUCTASE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NONPARAMETRIC TEST; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADMINISTRATION, ORAL; ADULT; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NADPH-FERRIHEMOPROTEIN REDUCTASE; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84876737381     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1432-1     Document Type: Article

References (25)

1. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836-847
2. Iwasaki K (2007) Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22:328-335
3. Roy JN, Barama A, Poirier C, Vinet B, Roger M (2006) Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 16:659-665
4. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294
5. Cheung CY, Op den Buijsch RA, Wong KM, Chan HW, Chau KF, Li CS, Leung KT, Kwan TH, de Vrie JE, Wijnen PA et al (2006) Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 7:563-574
6. Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, Ogura Y, Oike F, Takada Y, Egawa H et al (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80:331-345
7. Suzuki Y, Homma M, Doki K, Itagaki F, Kohda Y (2008) Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. Br J Clin Pharmacol 66:154-155
8. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK (2008) Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 64:1069-1084
9. Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49:141-175
10. Hart SN, Zhong XB (2008) P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4:439-452
11. Huang N, Agrawal V, Giacomini KM, Miller WL (2008) Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 105:1733-1738
12. Fluck CE, Mullis PE, Pandey AV (2010) Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem Biophys Res Commun 401(1):149-153
13. Agrawal V, Choi JH, Giacomini KM, Miller WL (2010) Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 20(10):611-618
14. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB (2009) The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 19(11):877-883
15. Yang G, Fu Z, Chen X, Yuan H, Yang H, Huang Y, Ouyang D, Tan Z, Tan H, Huang Z, Zhou H (2011) Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. Clin Ther 33(12):2060-2070
16. De Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR (2011) The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12:1281-1291
17. Miao LY, Huang CR, Hou JQ, Qian MY (2008) Association study of abcb1 and cyp3a5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 29:1-5
18. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, Zanger UM (2009) Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10:579-599
19. Chen YL, Hirabayashi H, Akhtar S, Pelzer M, Kobayashi M (2006) Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 830:330-341
20. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, Chun BG, Shin JG, Park JY (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 80:646-656
21. Hubbard PA, Shen AL, Paschke R, Kasper CB, Kim JJ (2001) NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 276:29163-29170
22. Fluck CE, Nicolo C, Pandey AV (2007) Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam Clin Pharmacol 21:399-410
23. Hamdane D, Xia C, Im SC, Zhang H, Kim JJ, Waskell L (2009) Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450. J Biol Chem 284:11374-11384
24. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779
25. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391